{"id":"W2955031471","doi":"10.1161/circulationaha.119.039609","title":"Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease","year":2019,"lang":"en","type":"article","venue":"Circulation","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute","funders":"Idorsia Pharmaceuticals; Servier; Eisai; Belvoir Media Group; Duke Clinical Research Institute; Novo Nordisk; Medicines Company; St. Jude Medical; Regeneron Pharmaceuticals; Amarin Corporation; Boston Scientific Corporation; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ironwood Pharmaceuticals, Incorporated","keywords":"Medicine; Rivaroxaban; Aspirin; Internal medicine; Heart failure; Myocardial infarction; Coronary artery disease; Cardiology; Stroke (engine); Ejection fraction; Adverse effect; Hazard ratio; Warfarin; Atrial fibrillation; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004757887,0.0001237426,0.0002125873,0.00008598356,0.00003478564,0.00002384605,0.0000207828,0.00003630975,0.0002863407],"category_scores_gemma":[0.00001177414,0.00007527258,0.00002179349,0.0001572808,0.00003117175,0.0002442399,0.00001496891,0.00006175624,0.00001942026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001078826,"about_ca_system_score_gemma":0.00009432333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006547225,"about_ca_topic_score_gemma":0.0000739359,"domain_scores_codex":[0.9992362,0.00002406218,0.0001468754,0.0002297476,0.0002233542,0.0001397909],"domain_scores_gemma":[0.9996088,0.00001928403,0.00005731652,0.0001785422,0.00004889441,0.00008719934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00296797,0.00001531081,0.995706,0.0001243498,0.00002560828,0.000007081258,0.0000628389,0.0004083654,0.00004072683,0.00002312229,0.00002803269,0.0005905963],"study_design_scores_gemma":[0.006495151,0.0004669412,0.9889739,0.000173845,0.0000623652,0.000004619313,0.00004927701,0.002450921,0.000002263754,0.000006845833,0.001181235,0.0001326435],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978914,0.00002140547,0.0001238135,0.000669107,0.00004341939,0.001143122,0.000002056079,0.00003966549,0.00006602219],"genre_scores_gemma":[0.9986427,0.000001270242,0.0003149885,0.0001750766,0.0001225142,0.000005055819,0.0001153658,0.00002141493,0.0006016298],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006732105,"threshold_uncertainty_score":0.3135231,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01931170759897828,"score_gpt":0.2660936462790983,"score_spread":0.24678193868012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}